Global Guidance for Evidence-Based Value Assessment of Innovative Health Technologies: Feasible Reality or Idealistic Dream?

Moderator

Durhane Wong-Rieger, PhD, Canadian Organization for Rare Disorders, Toronto, ON, Canada

Speakers

Alan Balch, MS, PhD, Patient Advocate Foundation and National Patient Advocate Foundation, Hampton, VA, United States; Marina Richardson, ICER, Boston, MA, United States; Lou Garrison, PhD, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Seattle, WA, United States

Innovative technologies—such as cell and gene therapies, molecular diagnostics, and targeted treatments— harbour the potential to change patient lives and bring substantial benefits to health systems. Assessing and accurately measuring their value for patients, health systems, and society at large is critical. However, health technology assessment bodies face challenges in incorporating evaluation criteria and methodologies that capture extended sets of potential value drivers, such as those found in the ISPOR Value Flower and the Generalized Cost-Effectiveness Analysis (GCEA) framework. This session will debate if these novel value drivers are a feasible and indeed ethical solution for assessing innovative health technologies, and whether global guidance for their incorporation can be a pathway to strengthen value assessments for future-proof health systems.

Code

138

Topic

Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment